Skip to main content
NCBI home page
Gut logoLink to Gut
. 1996 Apr;38(4):578–581. doi: 10.1136/gut.38.4.578

Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors.

F M Giardiello 1, J A Offerhaus 1, A C Tersmette 1, L M Hylind 1, A J Krush 1, J D Brensinger 1, S V Booker 1, S R Hamilton 1
PMCID: PMC1383118  PMID: 8707091

Abstract

BACKGROUND--Sulindac, a non-steroidal anti-inflammatory drug, causes regression of colorectal adenomas in patients with familial adenomatous polyposis (FAP) but the response is variable. Specific clinical factors predictive of sulindac induced regression have not been studied. METHODS--22 patients with FAP were given sulindac 150 mg orally twice a day. Polyp number and size were determined before treatment and at three months. The relation of nine clinical factors to polyp regression (per cent of baseline polyp number after treatment) was evaluated by univariate and multivariate analysis. RESULTS--After three months of sulindac, polyp number had decreased to 45 per cent of baseline and polyp size to 50 per cent of baseline (p < 0.001 and p < 0.01, respectively). Univariate analysis showed greater polyp regression in older patients (p = 0.004), those with previous colectomy and ileorectal anastomosis (p = 0.001), and patients without identifiable mutation of the APC gene responsible for FAP (p = 0.05). With multivariate regression analysis, response to sulindac treatment was associated with previous subtotal colectomy. CONCLUSIONS--Sulindac treatment seems effective in producing regression of colorectal adenomas of FAP patients with previous subtotal colectomy regardless of baseline polyp number and size. Changed sulindac metabolism, reduced area of the target mucosa, or changed epithelial characteristics after ileorectal anastomosis may explain these findings.

Full text

PDF
578

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Debinski H. S., Trojan J., Nugent K. P., Spigelman A. D., Phillips R. K. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet. 1995 Apr 1;345(8953):855–856. [PubMed] [Google Scholar]
  2. Duggan D. E., Hooke K. F., Risley E. A., Shen T. Y., Arman C. G. Identification of the biologically active form of sulindac. J Pharmacol Exp Ther. 1977 Apr;201(1):8–13. [PubMed] [Google Scholar]
  3. Farmer K. C., Phillips R. K. Colectomy with ileorectal anastomosis lowers rectal mucosal cell proliferation in familial adenomatous polyposis. Dis Colon Rectum. 1993 Feb;36(2):167–171. doi: 10.1007/BF02051173. [DOI] [PubMed] [Google Scholar]
  4. Giardiello F. M., Hamilton S. R., Krush A. J., Piantadosi S., Hylind L. M., Celano P., Booker S. V., Robinson C. R., Offerhaus G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993 May 6;328(18):1313–1316. doi: 10.1056/NEJM199305063281805. [DOI] [PubMed] [Google Scholar]
  5. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H., Joslyn G., Stevens J., Spirio L., Robertson M. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991 Aug 9;66(3):589–600. doi: 10.1016/0092-8674(81)90021-0. [DOI] [PubMed] [Google Scholar]
  6. Hixson L. J., Alberts D. S., Krutzsch M., Einsphar J., Brendel K., Gross P. H., Paranka N. S., Baier M., Emerson S., Pamukcu R. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):433–438. [PubMed] [Google Scholar]
  7. Hucker H. B., Stauffer S. C., White S. D., Rhodes R. E., Arison B. H., Umbenhauer E. R., Bower R. J., McMahon F. G. Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluro-2-methyl-1-(p-(methylsulfinyl)-benzylidenyl)-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. Drug Metab Dispos. 1973 Nov-Dec;1(6):721–736. [PubMed] [Google Scholar]
  8. Kinzler K. W., Nilbert M. C., Su L. K., Vogelstein B., Bryan T. M., Levy D. B., Smith K. J., Preisinger A. C., Hedge P., McKechnie D. Identification of FAP locus genes from chromosome 5q21. Science. 1991 Aug 9;253(5020):661–665. doi: 10.1126/science.1651562. [DOI] [PubMed] [Google Scholar]
  9. Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., Duhamel O., Trousset M., Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991 Sep;101(3):635–639. doi: 10.1016/0016-5085(91)90519-q. [DOI] [PubMed] [Google Scholar]
  10. Miyoshi Y., Ando H., Nagase H., Nishisho I., Horii A., Miki Y., Mori T., Utsunomiya J., Baba S., Petersen G. Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4452–4456. doi: 10.1073/pnas.89.10.4452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Niv Y., Fraser G. M. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology. 1994 Sep;107(3):854–857. doi: 10.1016/0016-5085(94)90136-8. [DOI] [PubMed] [Google Scholar]
  12. Nugent K. P., Farmer K. C., Spigelman A. D., Williams C. B., Phillips R. K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993 Dec;80(12):1618–1619. doi: 10.1002/bjs.1800801244. [DOI] [PubMed] [Google Scholar]
  13. Pasricha P. J., Bedi A., O'Connor K., Rashid A., Akhtar A. J., Zahurak M. L., Piantadosi S., Hamilton S. R., Giardiello F. M. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology. 1995 Sep;109(3):994–998. doi: 10.1016/0016-5085(95)90411-5. [DOI] [PubMed] [Google Scholar]
  14. Powell S. M., Petersen G. M., Krush A. J., Booker S., Jen J., Giardiello F. M., Hamilton S. R., Vogelstein B., Kinzler K. W. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med. 1993 Dec 30;329(27):1982–1987. doi: 10.1056/NEJM199312303292702. [DOI] [PubMed] [Google Scholar]
  15. Rao C. V., Rivenson A., Simi B., Zang E., Kelloff G., Steele V., Reddy B. S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 1995 Apr 1;55(7):1464–1472. [PubMed] [Google Scholar]
  16. Shen T. Y., Winter C. A. Chemical and biological studies on indomethacin, sulindac and their analogs. Adv Drug Res. 1977;12:90–245. [PubMed] [Google Scholar]
  17. Thorson A. G., Lynch H. T., Smyrk T. C. Rectal cancer in FAP patient after sulindac. Lancet. 1994 Jan 15;343(8890):180–180. doi: 10.1016/s0140-6736(94)90974-1. [DOI] [PubMed] [Google Scholar]
  18. Waddell W. R., Loughry R. W. Sulindac for polyposis of the colon. J Surg Oncol. 1983 Sep;24(1):83–87. doi: 10.1002/jso.2930240119. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES